HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Budget: Compounding Increase Paid With Construction Funding, Efficiencies

This article was originally published in The Tan Sheet

Executive Summary

Some planned buildings on the White Oak campus for fiscal 2015 would not be funded and savings from program efficiencies would create the $25 million in new funding for compounding oversight, Hamburg tells House committee.

You may also be interested in...



FDA Headquarters Consolidation Does Not Slow Outside Rent Growth

President Obama’s budget requests less headquarters consolidation funding in fiscal 2015. Outside rent spending in the budget request increased from $116.4 million to $120.9 million due to “escalating costs in commercial rent, security, service contracts and utilities,” according to FDA’s congressional justification.

FDA Gets $91 Million Boost, Sequestered User Fees In 2014 Appropriation

A 2014 omnibus appropriations bill agreed to by Senate and House appropriators would give FDA $2.55 billion in discretionary funding, a $91 million increase. In news applauded by the device industry, the bill would also make available $85 million in previously sequestered FDA user fees.

FDA Mandates Need Accompanying Resources, Hamburg Says

The mandates in the FDA Safety and Innovation Act and Drug Quality and Security Act show a lot of congressional confidence in the agency, but FDA commissioner says that members also must provide resources to go with it.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS139343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel